Deter Russell L, Lee Wesley, Kingdom John C P, Romero Roberto
a Department of Obstetrics and Gynecology , Texas Children's Hospital, Baylor College of Medicine , Houston , TX , USA.
b Division of Maternal-Fetal Medicine , Mount Sinai Hospital, University of Toronto , Toronto , Ontario , Canada.
J Matern Fetal Neonatal Med. 2018 Apr;31(7):866-876. doi: 10.1080/14767058.2017.1300646. Epub 2017 Mar 20.
To study fetal growth in pregnancies at risk for growth restriction (GR) using, for the first time, the fetal growth pathology score (FGPS1).
A retrospective cohort study of GR was carried out in 184 selected SGA singletons using a novel, composite measure of growth abnormalities termed the FGPS1. Serial fetal biometry was used to establish second trimester Rossavik size models and determine FGPS1 values prior to delivery. FGPS1 data were compared to neonatal growth outcomes assessed using growth potential realization index (GPRI) values (average negative pathological GPRI (av - pGPRI)). Growth at the end of pregnancy was evaluated from differences in negative, individual composite prenatal growth assessment scores (-icPGAS) measured at the last two ultrasound scans. The FGPS1 and av - pGPRI values were used to classify fetal growth and neonatal growth outcomes, respectively, as Normal (N) or Abnormal (A).
The risk of neonatal GR (based on birth weight (BW)) was moderate (MR: between 5th and10th percentiles (n = 113)) or significant (SR:<5th percentile) (n = 71)). Individual pregnancies were grouped into four categories, two representing agreement (N-N (29%), A-A (40%)) and two representing discordance (N-A (11%), A-N (20%)). In the largest and most variable subgroup (A-A,<5%tile, n = 49), there was a statistically significant correlation (0.63, p < .0001) between the FGPS1 and av - pGPRI. In N-A, all 20 cases (100%) had long last-scan-to-delivery intervals (1.9 weeks or greater), suggesting late development of the growth abnormality. For A-N, in approximately equal proportions, GR was improving, progressing or unclassifiable at the end of pregnancy.
Significant agreement between prenatal and postnatal growth assessments was found using a novel approach for quantifying fetal growth pathology (FGPS1). Discordances appear to be due to lack of appropriate prenatal scans or an inadequate set of neonatal measurements. Evidence for a quantitative relationship between assessment methods was seen in the largest and most variable subgroup. The FGPS1 has the potential for characterizing GR in the third trimester and may provide a means for predicting the severity of corresponding abnormal neonatal growth outcomes.
首次使用胎儿生长病理评分(FGPS1)研究存在生长受限(GR)风险的妊娠中的胎儿生长情况。
对184例选定的小于胎龄单胎妊娠进行GR的回顾性队列研究,使用一种称为FGPS1的新型生长异常综合测量方法。采用系列胎儿生物测量法建立孕中期Rossavik大小模型,并在分娩前确定FGPS1值。将FGPS1数据与使用生长潜力实现指数(GPRI)值(平均负病理GPRI(av - pGPRI))评估的新生儿生长结局进行比较。根据最后两次超声扫描测量的个体负性综合产前生长评估分数(-icPGAS)的差异评估妊娠末期的生长情况。FGPS1值和av - pGPRI值分别用于将胎儿生长和新生儿生长结局分类为正常(N)或异常(A)。
新生儿GR(基于出生体重(BW))的风险为中度(MR:第5至第10百分位数之间(n = 113))或显著(SR:<第5百分位数)(n = 71))。个体妊娠分为四类,两类表示一致(N - N(29%),A - A(40%)),两类表示不一致(N - A(11%),A - N(20%))。在最大且变化最大的亚组(A - A,<第5百分位数,n = 49)中,FGPS1与av - pGPRI之间存在统计学显著相关性(0.63,p <.0001)。在N - A组中,所有20例病例(100%)的末次扫描至分娩间隔时间长(1.9周或更长),表明生长异常出现较晚。对于A - N组,在妊娠末期,GR改善、进展或无法分类的比例大致相等。
使用一种量化胎儿生长病理的新方法(FGPS1)发现产前和产后生长评估之间存在显著一致性。不一致似乎是由于缺乏适当的产前扫描或新生儿测量指标不完整所致。在最大且变化最大的亚组中可见评估方法之间存在定量关系的证据。FGPS1有可能在孕晚期对GR进行特征化描述,并可能为预测相应异常新生儿生长结局的严重程度提供一种手段。